{"doi":"10.7150/thno.69119","title":"Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death","abstract":null,"journal":"Theranostics","year":2022,"id":661993,"datarank":0.7357912167657645,"base_score":4.90527477843843,"endowment":4.90527477843843,"self_citation_contribution":0.7357912167657645,"citation_network_contribution":0.0,"self_endowment_contribution":0.7357912167657645,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":134,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1728203,"name":"Man Kyu Shim","orcid":null,"position":1,"is_corresponding":false},{"id":462027,"name":"Jiwoong Choi","orcid":"0000-0002-7427-2979","position":2,"is_corresponding":false},{"id":1728204,"name":"Suah Yang","orcid":null,"position":3,"is_corresponding":false},{"id":1728205,"name":"Jinseong Kim","orcid":null,"position":4,"is_corresponding":false},{"id":1728206,"name":"Wan Su Yun","orcid":null,"position":5,"is_corresponding":false},{"id":1728207,"name":"Hanhee Cho","orcid":null,"position":6,"is_corresponding":false},{"id":1728208,"name":"Jung Yeon Park","orcid":null,"position":7,"is_corresponding":false},{"id":1414927,"name":"Yongju Kim","orcid":"0000-0002-5862-5228","position":8,"is_corresponding":false},{"id":1728211,"name":"Joon-Kyung Seong","orcid":null,"position":9,"is_corresponding":false},{"id":1728213,"name":"Kwangmeyung Kim","orcid":null,"position":10,"is_corresponding":false},{"id":1728202,"name":"Yujeong Moon","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death","abstract":"Rationale: Cancer immunotherapy combining immune checkpoint blockade (ICB) with chemotherapeutic drugs has provided significant clinical advances. However, such combination therapeutic regimen has suffered from severe toxicity of both drugs and low response rate of patients. In this study, we propose anti-PD-L1 peptide-conjugated prodrug nanoparticles (PD-NPs) to overcome these obstacles of current cancer immunotherapy. Methods: The functional peptide, consisted of anti-PD-L1 peptide and cathepsin B-specific cleavable peptide, is conjugated to a doxorubicin (DOX), resulting in prodrug nanoparticles of PD-NPs via intermolecular interactions. The antitumor efficacy and immune responses with minimal side effects by PD-NPs combining PD-L1 blockade and ICD are evaluated in breast tumor models.","is_dataset_classified":null,"base_score":4.90527477843843,"endowment":4.90527477843843,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35265195","pmcid":"PMC8899589","openalex_id":"https://openalex.org/W4210831098","authors":[],"funders":[],"total_grants":0,"fwci":11.0633,"citation_percentile":0.9904544,"influential_citations":0,"citation_trend":[{"year":2022,"count":18},{"year":2023,"count":36},{"year":2024,"count":32},{"year":2025,"count":33},{"year":2026,"count":15}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.thno.org/v12p1999.pdf","host_type":"journal"},{"url":"https://www.thno.org/v12p1999.pdf","host_type":"publisher"},{"url":"https://www.thno.org/v12p1999.htm","host_type":"publisher"},{"url":"https://doi.org/10.7150/thno.69119","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/35265195","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8899589","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC8899589","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC8899589?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","Nanoplatforms for cancer theranostics","Immunotherapy and Immune Responses","B7-H1 Antigen","Cell Line, Tumor","Doxorubicin","Humans","Immunogenic Cell Death","Immunotherapy","Nanoparticles","Neoplasms","Peptides","Prodrugs"],"mesh_terms":["Immunogenic Cell Death","Doxorubicin","Humans","Immunotherapy","Neoplasms","Peptides","Prodrugs","Cell Line, Tumor","Nanoparticles","B7-H1 Antigen"],"keywords":["Immunotherapy","Blockade","Cancer immunotherapy","Immunogenic cell death","Prodrug","Conjugated system","PD-L1","Peptide","Immune checkpoint","Cancer research","Cancer","Medicine","Chemistry","Pharmacology","Receptor","Internal medicine","Biochemistry","Drug Delivery","Immune Checkpoint Blockade","Antitumor Immune Response","Prodrug Nanoparticle"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-12T12:10:59.327204Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}